Albert David
695.20
+7.70(+1.12%)
Market Cap₹396.76 Cr
PE Ratio-26.14
IndustryHealthcare
Company Performance:
1D+1.12%
1M-7.64%
6M-17.17%
1Y-40.23%
5Y+52.94%
View Company Insightsright
More news about Albert David
02Aug 25
Albert David Reports 59% Decline in Q1 Net Profit, Appoints New Independent Director
Albert David Limited's Q1 net profit declined by 59.30% to ₹77.50 million from ₹190.40 million year-over-year. The Board approved Q1 financial results and appointed Dr. Rajiv Anant Desai as Additional Non-Executive Independent Director for five years, effective August 2, subject to shareholder approval. Dr. Desai brings 38 years of pharmaceutical industry experience, including roles at Indian Pharmaceutical Alliance and Lupin Limited.
 no imag found
13May 25
Albert David Ltd Reports Q4 FY23 Results: EBITDA Loss Widens, Revenue Declines; Recommends Dividend
Albert David Ltd's Q4 FY23 results show a 15.94% YoY revenue decline to ₹749.00 crore. EBITDA swung to a loss of ₹48.00 crore from a profit of ₹96.00 crore in Q4 FY22. Net loss improved by 20.16% YoY to ₹103.00 crore. The company recommended a dividend of ₹5 per equity share despite financial challenges.
 no imag found
Albert David
695.20
+7.70
(+1.12%)
1 Year Returns:-40.23%
Industry Peers
Sun Pharmaceutical
1,702.60
(-0.11%)
Divis Laboratories
6,141.50
(+1.44%)
Torrent Pharmaceuticals
3,976.40
(-1.17%)
Cipla
1,333.30
(+0.50%)
Dr Reddys Laboratories
1,244.90
(+0.38%)
Lupin
2,218.50
(+1.06%)
Zydus Life Science
905.00
(-0.03%)
Mankind Pharma
2,080.40
(-0.43%)
Aurobindo Pharma
1,181.60
(-2.56%)
Alkem Laboratories
5,662.50
(+0.16%)